- Home
- UNCY vs RAPT Comparison
UNCY vs RAPT Comparison
Compare UNCY & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- RAPT
- Stock Information
- Founded
- UNCY 2016
- RAPT 2015
- Country
- UNCY United States
- RAPT United States
- Employees
- UNCY N/A
- RAPT N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- RAPT Health Care
- Exchange
- UNCY Nasdaq
- RAPT Nasdaq
- Market Cap
- UNCY 58.7M
- RAPT 59.1M
- IPO Year
- UNCY 2021
- RAPT 2019
- Fundamental
- Price
- UNCY $0.62
- RAPT $1.25
- Analyst Decision
- UNCY Strong Buy
- RAPT Hold
- Analyst Count
- UNCY 4
- RAPT 10
- Target Price
- UNCY $5.50
- RAPT $6.00
- AVG Volume (30 Days)
- UNCY 1.0M
- RAPT 627.1K
- Earning Date
- UNCY 03-27-2025
- RAPT 03-06-2025
- Dividend Yield
- UNCY N/A
- RAPT N/A
- EPS Growth
- UNCY N/A
- RAPT N/A
- EPS
- UNCY N/A
- RAPT N/A
- Revenue
- UNCY N/A
- RAPT N/A
- Revenue This Year
- UNCY N/A
- RAPT N/A
- Revenue Next Year
- UNCY N/A
- RAPT N/A
- P/E Ratio
- UNCY N/A
- RAPT N/A
- Revenue Growth
- UNCY N/A
- RAPT N/A
- 52 Week Low
- UNCY $0.20
- RAPT $0.79
- 52 Week High
- UNCY $1.80
- RAPT $10.05
- Technical
- Relative Strength Index (RSI)
- UNCY 51.79
- RAPT 53.72
- Support Level
- UNCY $0.57
- RAPT $1.10
- Resistance Level
- UNCY $0.65
- RAPT $1.30
- Average True Range (ATR)
- UNCY 0.05
- RAPT 0.09
- MACD
- UNCY 0.01
- RAPT 0.02
- Stochastic Oscillator
- UNCY 76.36
- RAPT 72.00
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.